Betamethasone / dexamethasone for fetal lung maturation — candidacy, dosing, the benefit window, and rescue-course decisions before anticipated preterm birth
Antenatal corticosteroids (ACS) are one of the highest-yield interventions in modern obstetrics: a single course given to the right patient, at the right gestational age, with a genuine risk of imminent preterm birth, meaningfully lowers neonatal death, respiratory distress syndrome (RDS), intraventricular hemorrhage (IVH), and necrotizing enterocolitis (NEC). The entire clinical skill is in correctly identifying candidacy — matching the intervention to a patient who is truly likely to deliver within the benefit window, rather than reflexively dosing everyone who walks into triage with contractions.
Any pregnant patient between 24+0 and 34+6 weeks who has a meaningful probability of delivering within the next 7 days is a candidate for a single course of antenatal corticosteroids. Qualifying clinical scenarios include:
• Threatened preterm labor with cervical change (dilation, effacement) or regular, painful contractions on tocodynamometry • Preterm prelabor rupture of membranes (PPROM) — corticosteroids reduce RDS without a clear increase in maternal or neonatal infection risk at these gestational ages • Preeclampsia / other hypertensive disease of pregnancy severe enough to prompt expectant management with anticipated delivery • A planned or medically indicated preterm delivery (e.g., worsening fetal growth restriction with abnormal Dopplers, placental abruption, non-reassuring fetal status) — steroids should be scheduled to precede a planned delivery when time allows • Multiple gestation with any of the above
Adjunct tools such as cervical length ultrasound or fetal fibronectin can support the estimate of imminent delivery risk, but a low fFN or reassuring cervical length should not be used to withhold steroids when the overall clinical picture (active contractions, advancing dilation, ruptured membranes) already indicates high risk. Conversely, steroids are not indicated for a patient with no identifiable risk factor for preterm birth simply because she is in the eligible gestational age range — the intervention is risk-triggered, not gestational-age-triggered alone.
Below 24 weeks, data on neonatal benefit are limited and periviability counseling dominates the decision (individualized, shared decision-making from ~22–23 weeks in some centers). Above 34+6 weeks, the original trials showed no meaningful RDS benefit until the ALPS-defined late-preterm extension (Stage 5) reopened a narrower indication up to 36+6 weeks.
Do not delay administration while awaiting a "definitive" diagnosis (e.g., formal PPROM confirmation, tocolysis response) if the overall clinical suspicion for delivery within 7 days is high — the first dose should be given as soon as the risk is recognized.
Two glucocorticoid regimens are used interchangeably worldwide, both producing comparable reductions in neonatal respiratory morbidity when the course is completed. The choice between them is largely one of local availability, formulation, and historical practice rather than proven superiority of one agent — but the pharmacologic target is the same: the fetal type II pneumocyte and its glucocorticoid receptor.
Practical dosing:
• Betamethasone: 12 mg intramuscularly, repeated once 24 hours later (2 doses total) — the more commonly used North American regimen • Dexamethasone: 6 mg intramuscularly every 12 hours for 4 doses — common in many international settings and typically less expensive
Both are synthetic, fluorinated glucocorticoids selected specifically because — unlike endogenous cortisol — they are poorly metabolized by placental 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2), the enzyme that normally shields the fetus from maternal cortisol. This allows a pharmacologic dose to reach the fetal circulation intact.
Mechanism in the fetal lung:
1. The synthetic glucocorticoid diffuses into type II alveolar pneumocytes and binds the cytoplasmic glucocorticoid receptor 2. The hormone–receptor complex translocates to the nucleus and acts as a transcription factor, inducing expression of surfactant protein genes SP-A, SP-B, SP-C, and SP-D 3. Type II pneumocytes increase production and packaging of surfactant phospholipids and proteins into lamellar bodies, which are then secreted into the alveolar lumen, lowering surface tension at the air–liquid interface and preventing alveolar collapse at end-expiration 4. In parallel, glucocorticoids accelerate structural lung maturation — thinning of the alveolar septae and mesenchyme, increasing the surface area available for gas exchange 5. Glucocorticoids also upregulate epithelial sodium channels (ENaC) in the airway epithelium, which drives active reabsorption of fetal lung fluid around the time of birth — an effect that reduces transient tachypnea of the newborn as well as RDS
The net effect is a fetal lung that behaves, functionally, several days to a couple of weeks more mature than its actual gestational age would predict — but this effect is time-limited (see Stage 3).
Betamethasone and dexamethasone produce statistically equivalent reductions in RDS in head-to-head trials; some data suggest a possible difference in IVH risk favoring betamethasone, which influences preference in some units, but either is an acceptable choice when only one is available.
Antenatal corticosteroids do not confer a permanent change in fetal lung biology — they open a temporary, self-limited window of enhanced maturity. Correctly timing administration relative to the anticipated delivery date is what separates a course that meaningfully reduces RDS from one given so early or so late that most of its benefit has already dissipated.
The Cochrane systematic review (Roberts et al. 2020, >11,000 women, >30 trials) remains the cornerstone evidence base for antenatal corticosteroids. Compared with no treatment, a completed course reduces:
• RDS (relative risk ≈ 0.66, roughly a 34% relative reduction) • Neonatal death (RR ≈ 0.78) • Intraventricular hemorrhage (RR ≈ 0.55) • Necrotizing enterocolitis (RR ≈ 0.50) • Need for mechanical ventilation and surfactant replacement therapy • Systemic infection in the first 48 hours of life
These benefits are concentrated in infants delivered within the optimal window — from roughly 24 hours after the first dose (which for betamethasone approximates completion of the 2-dose course) out to about 7 days after course completion. This is the interval during which surfactant protein transcription, lamellar body accumulation, and ENaC-mediated fluid clearance are maximally upregulated.
Too early — delivery within 24 hours of the first dose, or with an incomplete course: The fetus has not yet had time to mount the full transcriptional response. Benefit is real but attenuated. Because delivery timing is frequently unpredictable, this is never a reason to withhold or delay the first dose — even a single dose confers partial benefit, and roughly half of treated pregnancies will deliver before the second dose is due.
Too late — delivery more than 7–14 days after course completion: The induced changes are transient. Surfactant protein transcription returns toward baseline, and by 2 weeks post-course the treated fetal lung is difficult to distinguish, functionally, from an untreated one of the same gestational age. Delivery occurring 14+ days after a course therefore derives little ongoing benefit from that course — this is precisely the scenario that raises the question of a rescue course (Stage 4).
Give the first dose as soon as delivery risk within 7 days is recognized, even if delivery is expected in a matter of hours — partial-course exposure still reduces RDS risk, and you cannot reliably predict whether the second dose will be reached.
Pregnancies at risk for preterm birth are frequently unpredictable — a patient treated at 26 weeks may remain undelivered at 30 weeks, well outside the original benefit window, and then develop a fresh episode of threatened preterm labor. This scenario is the specific indication for a single "rescue" or repeat course, a practice that is deliberately bounded to avoid the harms seen with unrestricted repeat dosing.
A single rescue course is appropriate when all of the following are true:
1. At least 14 days have elapsed since the prior completed course 2. Gestational age remains under 34+0 weeks 3. The patient has developed a new clinical risk of delivery within 7 days (recurrent threatened preterm labor with cervical change, new PPROM, new hypertensive disease, etc.)
Randomized trial evidence (notably the MFMU Network rescue-course trial) shows that a single repeat course further reduces the composite of RDS and other neonatal respiratory morbidity when delivery follows within the new benefit window, without a clear signal of harm at that single-repeat exposure level.
The picture changes with repeated, multi-course dosing. Earlier trials that tested weekly or serial courses (dosing every time the patient remained at risk, regardless of interval) found:
• Reduced birthweight and smaller head circumference at birth with 3 or more courses • Signals of altered neurodevelopmental and behavioral outcomes on longer-term follow-up in some cohorts • No added reduction in RDS beyond what a single completed course (± one rescue) already provides
Because of this dose–response harm signal, ACOG and SMFM guidance is explicit: administer at most one rescue course. Routine "weekly" or scheduled serial courses for a patient who remains chronically at risk are not recommended — clinicians should reassess risk at each new episode rather than pre-scheduling repeat doses.
A patient readmitted with threatened preterm labor at 31 weeks who completed a course at 25 weeks (6 weeks/42+ days prior) and remains under 34 weeks is an appropriate rescue-course candidate — but that same patient should not receive a third course two weeks later simply because she remains admitted.
For years, antenatal corticosteroids were withheld beyond 34 weeks because early trials showed no clear respiratory benefit at more advanced gestational ages. The Antenatal Late Preterm Steroids (ALPS) trial (Gyamfi-Bannerman et al., NEJM 2016) overturned that assumption for a specific population — but introduced a real, dose-limiting trade-off that changes counseling and postnatal monitoring rather than the indication itself.
ALPS enrolled women at 34+0–36+6 weeks judged to have a high probability of late-preterm delivery (planned delivery, or spontaneous risk factors) and randomized them to a single betamethasone course versus placebo. Betamethasone significantly reduced the primary composite outcome of severe respiratory complications in the first 72 hours of life — need for respiratory support, continuous positive airway pressure or high-flow oxygen for extended periods, extracorporeal membrane oxygenation, mechanical ventilation, stillbirth, or early neonatal death — alongside reductions in transient tachypnea of the newborn and surfactant use.
The trade-off: neonatal hypoglycemia was significantly more common in the betamethasone group. This is a known, transient, and manageable effect — glucocorticoid exposure alters fetal/neonatal glucose-insulin dynamics — but it requires routine postnatal glucose screening protocols in exposed neonates and should be part of counseling before treatment.
Practical exclusion criteria that limit the late-preterm indication:
• A patient who already received a full course of antenatal corticosteroids earlier in the same pregnancy is NOT eligible for an additional course in the late-preterm window — this is a one-time extension, not an additional rescue opportunity • Pregestational (insulin-treated) diabetes was excluded from the pivotal trial, so evidence for benefit/harm balance in that population is limited • Clinical chorioamnionitis: delivery should not be delayed to complete a steroid course when there is a maternal or fetal indication for immediate delivery
As with the earlier gestational-age window, the late-preterm indication is driven by an anticipated delivery within 7 days, not by gestational age alone.
A patient who received a course at 27 weeks and remains pregnant at 35 weeks with new risk of imminent delivery should NOT receive a second (late-preterm) course — she already received her one indicated course; the late-preterm extension applies only to patients who have not previously been treated in this pregnancy.